EverSource Wealth Advisors’s Pliant Therapeutics PLRX Stock Holding History

EverSource Wealth Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21	Closed	-$24	–	4439
2025 Q2	$24	Sell	21 -41	-66%	-$58	﹤0.01%	4219
2025 Q1	$84	Buy	+62	New	+$376	﹤0.01%	3851
2024 Q1	–	Sell	-59	Closed	-$1.07K	–	2966
2023 Q4	$1.07K	Buy	+59	New	+$897	﹤0.01%	2383

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

EverSource Wealth Advisors's PLRX Position: Q3 2025 in Review

EverSource Wealth Advisors sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 21 shares — an estimated $24 sold.

EverSource Wealth Advisors first reported a position in PLRX in Q4 2023 and held it in 3 quarters. The position peaked at $1.07K in Q4 2023. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

EverSource Wealth Advisors reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
EverSource Wealth Advisors sold 21 Pliant Therapeutics shares in Q3 2025, an estimated $24.
EverSource Wealth Advisors first reported a position in Pliant Therapeutics in Q4 2023 and held it in 3 quarters.
EverSource Wealth Advisors's Pliant Therapeutics position peaked at $1.07K in Q4 2023.
99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on EverSource Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.